Covaxin

After Covaxin and Covishield, the Union Health Ministry also approved Corbevax as a booster dose against Covid-19.  Biological E's Corbevax is allowed for double-vaccinated people above 18-years-old. The recommendations were given by the National Technical Advisory Group on Immunisation (NTAG). Corbevax, considered a precaution dose will be given six months or 26 weeks from the date of the second dose of either Covaxin/Covisheild. Necessary… read-more

The Covid-19 vaccine Corbevax, manufactured by BiologicalE in Hyderabad, is the first to be licensed as a heterologous booster in adults by Drugs Controller General of India. Individuals who had Covishield/Covaxin for their first two doses can get Corbevax as their third. Following the booster dosage of Corbevax, neutralizing antibodies against Omicron variation were identified in 91% of individuals who had received Covishield and in 75% who… read-more

The Haryana government has rolled out "free" booster doses for the 18-59 age group. The announcement came just days after the Delhi government made booster shots freely available for the age group. Around a whopping Rs 300 crores of taxpayers' money out of the state Covid-19 Relief Fund would be dedicated to this program. Experts are divided on the need for these "precautionary" doses.

The WHO suspended the supply of Covaxin, an India-made (Bharat Biotech) Covid-19 vaccine through UN agencies. The decision was taken to allow the manufacturer to upgrade facilities and address deficiencies found in an inspection. In a statement, the organization pointed out that the company needs facility upgrade, "For the coming period the company will focus on pending facility maintenance, process, and facility optimization activities," … read-more

The Drugs Controller General of India (DCGI) on January 27, granted regular market approval to India's Covaxin and Covishield vaccines against COVID-19. Following SEC's recommendations, the DCGI allowed only hospitals and clinics to purchase the SII's Covishield and Bharat Biotech's Covaxin under the New Drugs And Clinical Trials 2019 Act. However, the authority needs to submit data every six months to the DCGI and update on CoWIN app.